In clinical, osimertinib is given as a second-line treatment to the locally advanced or metastatic (stage IIIB/IV) NSCLC patients who have progressed following prior EGFR TKI therapy, and provides good clinical activity with minimal side effects (ORR = 70%) (Goss et al., 2016; Mok et al., 2017). Here, EGFR is linked to non-small cell lung carcinoma.